Digital health solutions provider Adherium has introduced Hailie solution in the US for better asthma and chronic obstructive pulmonary disease (COPD) management.
The company recently secured 510(k) over-the-counter clearance from the US Food and Drug Administration (FDA) to market the Hailie solution directly for the consumers.
The solution has been developed to provide patients with asthma and COPD better access through smartphone app available on both iOS and Android. A sensor will be attached to patient’s prescription inhaler medication.
It will help patients achieve better adherence through managing their condition. It enables to track medication use and reminds the user about doses to be taken at required time.
Adherium’s new solution will also offer visibility of medication use and adherence to parents and caregivers.
Adherium CEO Arik Anderson said: “Individuals and families with asthma and COPD can now access a solution that encompasses the world’s most clinically proven asthma and COPD medication adherence platform, cleverly packaged into the simplest interface.
“Hailie is the culmination of 15 years of accelerating research and development and is focused on the premise that if we are to turn the corner on treating chronic conditions, we have to make managing them second nature.”
Adherium is also introducing an online portal for healthcare professionals and clinicians to visualize and analyze patient-group data collected from Hailie sensors.
The platform will establish interaction between health professionals and patients by allowing sharing and monitoring of patient inhaler usage.
According to the company, Asthma continues to be the third-ranking cause of hospitalization for children under 15 years of age in the US.
Vitalus Health CEO Cody Patel said: “Adherence technology that fits naturally within a physician’s practice makes care seamless; it fosters a better understanding for patients, meeting a tremendous need.”
Adherium is engaged in the development, manufacturing and supplying a range of connected medical devices for respiratory medications to the pharmaceutical companies, healthcare providers and contract research organizations.
With headquarters in the US, the company operates across the globe from bases in the US, Europe and Australasia.